国邦医药
(605507)
| 流通市值：56.39亿 | | | 总市值：104.44亿 |
| 流通股本：3.02亿 | | | 总股本：5.59亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,338,703,044.52 | 5,349,447,853.45 | 4,053,476,803.52 | 2,809,720,242.62 |
| 营业收入 | 1,338,703,044.52 | 5,349,447,853.45 | 4,053,476,803.52 | 2,809,720,242.62 |
| 二、营业总成本 | 1,100,097,238.84 | 4,654,820,766.07 | 3,478,553,568.83 | 2,375,838,982.96 |
| 营业成本 | 971,460,846.31 | 4,097,118,775.12 | 3,054,170,655.22 | 2,117,473,724.27 |
| 税金及附加 | 6,975,135.41 | 36,192,864.06 | 23,117,921.02 | 16,493,811.15 |
| 销售费用 | 17,227,379.19 | 74,197,850.9 | 53,851,258.62 | 32,491,692.16 |
| 管理费用 | 75,746,168.31 | 303,082,905.26 | 229,549,906.85 | 152,448,229.13 |
| 研发费用 | 37,654,589.3 | 190,510,675.8 | 162,761,109.22 | 97,438,359.97 |
| 财务费用 | -8,966,879.68 | -46,282,305.07 | -44,897,282.1 | -40,506,833.72 |
| 其中:利息费用 | 7,423,041.75 | 22,581,864.31 | 18,200,731.36 | 9,485,790.21 |
| 其中:利息收入 | 10,769,739.38 | 51,781,507.48 | 41,476,064.25 | 29,867,621.96 |
| 加:公允价值变动收益 | -380,316.73 | 10,342,212.44 | - | 3,637,513.71 |
| 加:投资收益 | 7,269,026.85 | 13,221,073.8 | 4,671,446.73 | -1,444,517.19 |
| 资产减值损失(新) | -8,833,438.3 | -31,446,618.97 | -1,246,964.88 | -17,017,810.39 |
| 信用减值损失(新) | -4,492,387.76 | 4,720,350.79 | -19,809,511.65 | -4,719,172.39 |
| 其他收益 | 3,936,686.1 | 10,799,364.62 | 5,437,632.57 | 3,178,694.47 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 236,105,375.84 | 702,263,470.06 | 563,975,837.46 | 417,515,967.87 |
| 加:营业外收入 | 482,070.27 | 3,315,078.6 | 2,117,052.74 | 377,857.1 |
| 减:营业外支出 | 2,563,910.72 | 7,929,967.44 | 6,542,328.4 | 4,987,703.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 234,023,535.39 | 697,648,581.22 | 559,550,561.8 | 412,906,121.21 |
| 减:所得税费用 | 35,444,849.34 | 87,669,888.68 | 71,894,822.29 | 56,049,758.16 |
| 六、净利润 | 198,578,686.05 | 609,978,692.54 | 487,655,739.51 | 356,856,363.05 |
| 持续经营净利润 | 198,578,686.05 | 609,978,692.54 | 487,655,739.51 | 356,856,363.05 |
| 归属于母公司股东的净利润 | 198,731,128.32 | 612,464,147.66 | 489,073,265.39 | 357,470,775.26 |
| 少数股东损益 | -152,442.27 | -2,485,455.12 | -1,417,525.88 | -614,412.21 |
| (一)基本每股收益 | 0.36 | 1.1 | 0.88 | 0.64 |
| (二)稀释每股收益 | 0.36 | 1.1 | 0.88 | 0.64 |
| 九、综合收益总额 | 198,578,686.05 | 609,978,692.54 | 487,655,739.51 | 356,856,363.05 |
| 归属于母公司股东的综合收益总额 | 198,731,128.32 | 612,464,147.66 | 489,073,265.39 | 357,470,775.26 |
| 归属于少数股东的综合收益总额 | -152,442.27 | -2,485,455.12 | -1,417,525.88 | -614,412.21 |
| 公告日期 | 2024-04-16 | 2024-04-16 | 2023-10-19 | 2023-07-29 |
| 审计意见(境内) | | 标准无保留意见 | | |